More 60 Dermatology Tips in 60 Minutes from the Midwinter Clinical Hawaii Derm Conference
How to treat lichenoid dermatoses, what to do when the Quant Gold is indeterminate, pocket-sized Wood lights, plus 9 more pearls from the experts.
Pediatric Dermatology Treatment: An Expert Overview with Elizabeth Swanson, MD
From new biologics for AD to JAK inhibitors for children with alopecia areata, get the latest updates in pediatric dermatology, here.
A Case of Biologic Switching in Psoriasis and How to Optimize Outcomes with Ron Vender, MD
Switching biologic treatment for patients with moderate to severe psoriasis, needn't be daunting, Vender said; he works through a tricky case that ended very well.
FDA Approves GSK's Pentavalent Meningococcal Vaccine Penmenvy
The ACIP of the CDC will meet on February 26 to vote on recommendations for appropriate incorporation of Penmenvy into the routine vaccination schedule.
Pearls for Solving Problems when Treating Psoriasis: From the Experts
Dermatology experts share pearls to help when biologics alone are not enough, when obesity is a comorbidity with psoriasis, and when isotype switching derails therapy.
Topical Acne Therapies: A Clinical Update
Insights include new data on combination therapies, topical antiandrogens, and innovative retinoid formulations.
Alopecia Areata: Emerging Data and Treatment Approaches
JAK inhibitors are being used widely and successfully to treat alopecia areata, and Amy McMichaels, MD, showcased data and also discussed patient communication.
The Great Atopic Dermatitis Treatment Debate: Biologics vs JAK Inhibitors
There really is no debate - it's all about individualizing treatment for the patient, but Drs Neal Bhatia and Raj Chovatiya went head to head at Midwinter Hawaii.
Key Advances in Oral Therapies for Psoriasis Unveiled at Winter Clinical Dermatology Conference 2025
April Armstrong, MD, discussed the latest data on apremilast, deucravacitinib, and emerging TYK2 and IL-23 inhibitors at Midwinter Hawaii.
60 Tips in 60 Minutes: Day 1 at the 2025 Midwinter Clinical Hawaii Dermatology Conference
The dermatologic tips offered in this short slide show come from 4 renowned professionals and reflect their subspecialties.
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes
Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.
FDA Reviewing New Prefilled Syringe Formulation for GSK’s Shingrix
An FDA decision on GSK's Shingrix application is expected by June 20, 2025.
Robert F Kennedy, Jr, Confirmed to Lead HHS
After sometimes heated exchanges during confirmation hearings, the Senate vote was 52-48 in favor of RFK, Jr, with Sen Mitch McConnel the sole opposing Republican.
State Abortion Bans Cause Broad Disparity in Outcomes According to 2 Studies from Johns Hopkins Bloomberg School of Public Health
The 2 analyses of data on fertility and infant mortality were conducted in the first 14 states to impose complete or 6-week bans after the Dobbs decision in June 2022.
Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose
Your daily dose of the clinical news you may have missed.
The 2025 Winter Clinical Hawaii Dermatology Conference: Saturday Preview
The 2025 Winter Clinical Hawaii kicks off today with the first full day of educational sessions starting tomorrow, February 15 - here's what to look for.
Cannabis Use Disorder: FDA Grants Fast Track Status to Investigational Agent PP-01
The development comes at a time when cannabis use disorder has risen steadily in the United States.
5 Days in Hawaii: The Winter Clinical Hawaii Dermatology Conference
The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose
Dupilumab, Tezepelumab Gain Ground for Severe Asthma but Overall Biologic Adherence Rates Found Low: 2 Studies from 2025 AAAAI/WAO
AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.
